Axsome Therapeutics, Inc. (AXSM) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है New York City, NY, United States. वर्तमान CEO हैं Herriot Tabuteau.
AXSM के पास है IPO तिथि 2015-11-19, 712 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $9.42B.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders. The company's lead candidate, AXS-05, is being evaluated for major depressive disorder, treatment-resistant depression, Alzheimer's disease agitation, and smoking cessation across Phase II and Phase III clinical trials. Its pipeline also includes AXS-07 for acute migraine treatment, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, all in late-stage development. Founded in 2012 and headquartered in New York, Axsome collaborates with leading institutions including Duke University to advance its clinical programs.
